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of surgeons’ decision-making for one-stage
and two-stage revision surgery for
prosthetic hip joint infection
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Abstract
Background: Approximately 88,000 primary hip replacements are performed in England and Wales each year.
Around 1% go on to develop deep prosthetic joint infection. Between one-stage and two-stage revision arthroplasty
best treatment options remain unclear. Our aims were to characterise consultant orthopaedic surgeons’ decisions
about performing either one-stage or two-stage revision surgery for patients with deep prosthetic infection (PJI) after
hip arthroplasty, and to identify whether a randomised trial comparing one-stage with two-stage revision would
be feasible.
Methods: Semi-structured interviews were conducted with 12 consultant surgeons who perform revision surgery
for PJI after hip arthroplasty at 5 high-volume National Health Service (NHS) orthopaedic departments in England
and Wales. Surgeons were interviewed before the development of a multicentre randomised controlled trial. Data
were analysed using a thematic approach.
Results: There is no single standardised surgical intervention for the treatment of PJI. Surgeons balance multiple
factors when choosing a surgical strategy which include multiple patient-related factors, their own knowledge and
expertise, available infrastructure and the infecting organism. Surgeons questioned whether it was appropriate that the
two-stage revision remained the best treatment, and some surgeons' willingness to consider more one-stage revisions
had increased over recent years and were influenced by growing evidence showing equivalence between surgical
techniques, and local observations of successful one-stage revisions. Custom-made articulating spacers was a practice
that enabled uncertainty to be managed in the absence of definitive evidence about the superiority of one surgical
technique over the other. Surgeons highlighted the need for research evidence to inform practice and thought that
a randomised trial to compare treatments was needed. Most surgeons thought that patients who they treated would
be eligible for trial participation in instances where there was uncertainty about the best treatment option.
Conclusions: Surgeons highlighted the need for evidence to support their choice of revision. Some surgeons'
willingness to consider one-stage revision for infection had increased over time, largely influenced by evidence of
successful one-stage revisions. Custom-made articulating spacers also enabled surgeons to manage uncertainty
about the superiority of surgical techniques. Surgeons thought that a prospective randomised controlled trial
comparing one-stage with two-stage joint replacement is needed and that randomisation would be feasible.
Keywords: Decision-making, Prosthetic joint infection, Hip arthroplasty, Hip replacement, Orthopaedic surgery, Qualitative
* Correspondence: a.j.moore@bristol.ac.uk
School of Clinical Sciences, University of Bristol, Bristol, UK
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Moore et al. BMC Musculoskeletal Disorders  (2017) 18:154 
DOI 10.1186/s12891-017-1499-z
Background
Approximately 88,000 primary hip replacements were
performed in England and Wales during 2014 [1]. After
surgery, about 1% of patients subsequently develop deep
prosthetic joint infection (PJI) [2]. Treatment options for
early PJI can include non-surgical antimicrobial therapy,
or débridement with prosthesis retention. For more
established infections a prosthesis exchange is required
of which there are two types [3]. In a one-stage process,
the prosthesis is removed, the area debrided and a new
prosthesis is inserted immediately [4, 5]. In a two-stage
process, after removal of implants and debridement
there is often an interval period of around 3–6 months
during which systemic antibiotic therapy is delivered
and can be augmented by local delivery from a spacer
containing antibiotic loaded cement. A definitive pros-
thesis is then implanted during a second operation [5–7].
A variation on these one-stage or two-stage strategies is
the use of a custom-made articulating spacer (CUMARS).
This approach aims to provide the patient with a hip joint
between stages that can bear weight and provides rea-
sonable function. This technique involves the removal
of the implant and insertion of a new implant that is
“loosely” cemented into place. Although this first oper-
ation is intended to be the first of a two-stage process, if
the implant provides the patient with sufficient function
then a further operation is not conducted. Examples of
this method include the PROSTALAC [8] and CUMARS
hip [9]. Cases of CUMARS hip replacements remaining in
situ at 12 years follow-up have been reported [9].
All revision for infection has great impact on patients
[10], but patients undergoing two-stage revision report
that the period in between operations is particularly dif-
ficult, with reduced mobility and poor quality of life at
this time [10, 11]. Although two-stage revision provides
the opportunity for additional antimicrobial strategies
[12], around half of patients experience complications
associated with spacers [13] and the cost of a two-stage
revision for hip PJI is 1.7 times that of a one-stage revision
[14, 15]. Currently there is no adequately powered rando-
mised trial to determine the optimum treatment strategy
in PJI of the hip. The most recent high quality systematic
reviews in unselected patients indicate that re-infection
rates are relatively similar in one-stage and two-stage
revision [16, 17]. There is a paucity of evidence regarding
patient quality of life and satisfaction for the different
treatment strategies for PJI of the hip [18, 19]. Despite the
fact that two-stage revision is associated with higher surgi-
cal morbidity and mortality rates [20], it remains more
commonly performed than one-stage revision for PJI of
the hip (one-stage: 30%; two-stage: 64%; excision: 6% [21].
The design of high quality randomised controlled trials
(RCT) benefits from careful planning to consider factors
that might impede or facilitate recruitment and adherence
to protocols [22]. In any trial to compare surgical treat-
ments for PJI, there is a need to consider not only how
patients might view a trial, but also whether surgeons
are willing to be involved in a trial that necessarily
involves random allocation of patients to either one-stage
or two-stage surgery. This is particularly the case for PJI
because of the complex decisions that surgeons make
when deciding on what treatment is most appropriate. A
first step in trial design is identifying how these complex
decisions are made in current practice. This informa-
tion enables trial designers to establish feasibility of a
randomised trial and to inform elements of trial design.
To date no research has characterised how surgeons
make decisions about providing one-stage or two-stage
revision treatment for PJI. Understanding decision-
making requires attention to the detail and rationale
underpinning those decisions. A robust way to achieve
this is the use of qualitative research methods [23],
which are increasingly used to inform trial design [24, 25],
are recommended by the Medical Research Council [22]
and have demonstrable value across specialties including
orthopaedic surgery [26]. Using qualitative methods, we
characterised how orthopaedic surgeons decided to use
either one-stage or two-stage revision arthroplasty for
hip PJI and to assess the feasibility and inform the design
of a future randomised trial.
Methods
Setting and sampling
This qualitative interview study employed purposive
sampling and the sample size was designed to achieve
data saturation. Purposive sampling is used to ensure
that participants have experience of relevance to the
study question [26, 27] and data saturation is achieved
whereby collecting more data would not achieve further
insight [28]. An appropriate sample for this study com-
prised consultant orthopaedic surgeons who were making
decisions about treatment for hip PJI, and who regularly
conducted both one-stage and two-stage revision. The
sample size of 12 surgeons, as described below, was
adequate because data saturation was achieved. Twenty-
three surgeons from 5 high-volume National Health
Service (NHS) orthopaedic departments treating PJI
were invited to participate. A member of the study
team contacted each centre to identify eligible surgeons
and sent them an information pack, which included a
letter of invitation, information booklet, reply form and
pre-paid envelope. Surgeons who returned a reply form
that expressed their interest in taking part in the study
were contacted by a researcher who then made arrange-
ments for a face-to-face or telephone interview. All sur-
geons provided their written informed consent before
interview and all agreed to be audio-recorded and to the
publication of anonymised quotations from the interviews.
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Ethics approval for the study was granted by NRES
(National Research Ethics Service) Committee South
West —Exeter (14/SW/0072) on 29 April 2014.
Data collection and analysis
We conducted interviews with 12 orthopaedic surgeons,
either by telephone (n = 10) or face-to-face in an available
room at hospital (n = 2). The average age of the participants
was 49 years and all were men. Average number of years
treating infection was 14 (ranging from 3 to 23), see Table 1.
Interviews were conducted using a semi-structured topic
guide, focused on treatment of PJI, important outcomes,
and views about a future RCT [see Additional file 1]. The
interviews were conducted by an experienced qualitative
researcher (AJM), and lasted for an average of 29 min
(ranging from 16 to 44 min). Interviews were audio-
recorded, transcribed and anonymised.
The data were analysed using a thematic method [29],
which involved reading and re-reading the transcripts,
followed by initial inductive coding and grouping of the
data into themes and subthemes. Themes were further
refined to ensure internal and external coherence (fit
within the theme and externally within the whole data set)
[29]. To ensure rigour, four transcripts were independ-
ently double-coded by another experienced qualitative
researcher (RG-H), and codes discussed, agreed and
then applied to the data set with ongoing refinement as
needed. Data collection and analysis took place concur-
rently and data collection stopped once thematic saturation
was achieved [28]. All names are pseudonyms.
Results
We identified two overarching categories: “Making deci-
sions about revision” and “Views about a randomised con-
trolled trial” and a number of subthemes in each category.
These two key categories and all subthemes within them
are described in turn.
Making decisions about revision
A balance of patient and disease characteristics
Surgeons based their decision to perform either a one-stage
or two-stage revision on a balance between a complex mix
of patient physiology (patient’s age, condition of bone and
surrounding soft tissue), co-morbidities, cemented or un-
cemented primary fixation, the patient’s preference and
social situation, and the characteristics of the infecting
organism (for instance whether they could identify the
infecting organism and its antibiotic sensitivities):
For infection, if I know the organism, then I might
consider – or they’re elderly where they can’t really
survive without a hip, then there are situations where
I would go with a one-stage. But otherwise, the default
position is two-stage. (Dave)
My default is still two-stage, but if the patient’s young,
and they’ve got a cementless hip […] and the patient
comes in and has got a short-lived infection, I would
think more towards one-stage. So, so, generally, I
would say, if it’s a cemented hip, it gets a two-stage.
If it’s cementless, it gets a one-stage. But then there
are various things that will make me, veer the other
way. For instance, a diabetic, I would generally do in
two stages. (Tim)
Although surgeons made decisions based on patient
characteristics and the results of investigative tests and
radiographs before surgery, this decision could be revised
intraoperatively:
Table 1 Participant characteristics
No. Pseudonym Treatment centre Age (range in years) Years treating
PJI (range in years)
Revision type self-reported as performed
most often (one-stage, two-stage or CUMARS)
1 Steven Centre 1 35–50 0–10 Two-stage
2 Dave Centre 1 35–50 0–10 Two-stage
3 Tom Centre 2 35–50 0–10 CUMARS
4 Howard Centre 2 35–50 20+ CUMARS
5 Harrison Centre 3 35–50 0–10 CUMARS
6 James Centre 3 51–65 20+ Equal for one- and two-stage
7 Tim Centre 3 51–65 10–19 Two-stage
8 Carl Centre 3 51–65 10–19 CUMARS
9 Brian Centre 4 51–65 10–19 CUMARS
10 Duncan Centre 4 51–65 20+ CUMARS
11 Alex Centre 5 51–65 10–19 Two-stage
12 Saul Centre 5 35–50 10–19 Two-stage
Average 49 Average 14
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If I’m doing a single-stage revision for infection,
I would still warn the patient that if I find something
untoward intraoperatively then my default position
would be a two-stage. (Dave)
Sometimes in theatre, you get in there and you know,
with an infected hip, quite often the bone quality is
very poor […] And I think if the bone is soft, again,
I would rather do a two-stage, if I can. (Tim)
If patients required a two-stage revision a temporary
spacer loaded with antibiotics may be fitted for a period
of typically 3–6 months. Alternatively the surgeon may
choose not to use a spacer during this period. One sur-
geon explained that he thought that a two-stage strategy
increased the likelihood of eradicating the infection by
10% but saw this as a marginal gain when compared to
the prolonged treatment period and reduction in quality
of life for the patient:
There’s a benefit of having two because you get that
slightly higher, you know, but it’s only, you know, a 10
in 100 or whatever. It’s a, you know, or whatever it’s,
you know, 80 versus 90% - most people understand
that difference. […] They know it’s a marginal gain for
a big investment because it’s not just a second
operation. The main problem is for 2 or 3 months,
they’re gonna be incapacitated. To say they’re stuck at
home, unable to work, unable to get out and about,
dependent on other people for everything […]
That’s a long time isn’t it? Three months.
It is if you’ve only got a few years left to live,
yeah. (James)
Patients’ social and personal circumstances were also
taken into consideration:
So if the patient is the sort of patient who’s going to do
well with a pseudarthrosis of some sort, are they going
to struggle using crutches, have they got home
circumstances, because that might push you more
towards considering a one-stage, if all the other factors
are involved […] you may consider doing a one, even
though it may not be quite what you want because of
the patient factors, to improve their quality of life. (Saul)
Patients’ preferences
Surgeons reported that while some patients appear to be
happy to follow their advice and rely on the surgeon’s
decision, other patients had strong treatment preferences:
The other problem with doing a one-stage is trying to
convince the patients because quite a lot of patients
are coming along nowadays by the time they’ve come
to see myself or any of the other consultants […] they
have read up on infection and they know that there’s
a higher incidence of recurrence in a single stage
revision so very often they’re reluctant to have a
single stage. (Duncan)
Patients could also elect not to have any further surgery
if they felt they would prefer to go on long-term sup-
pressive antibiotics:
After you’ve discussed the situation with the patient,
discussed the potential for either a two-stage or a
one-stage procedure, some patients elect not to go
ahead. They’ve had enough of surgery. They may be
elderly. They may be frail. They may simply want to
go onto suppressive antibiotics, and accept the fact
that the hip is not perfect. (Alex)
Surgeons also indicated that for older or frailer patients,
the choice between surgery and long-term suppressive
antibiotics was also determined by how the patient feels
that their quality of life will be affected by the treatment.
The influence of infrastructure
The presence of physical and organisational structures
and facilities needed to ensure operations can be per-
formed are crucial. Surgeons suggested that deficits within
the infrastructure could impact on treatment decisions.
For instance, Duncan reported performing two-stage revi-
sions because local microbiology services were unable to
provide accurate service:
We didn’t until recently have the appropriate
infrastructure in [our hospital] with regard to the
microbiology department in order to be able to
identify organisms accurately prior to surgery […]
more often than not the aspirations would either
come back negative or the laboratory would have
some excuse as to why the sample hasn’t been tested
properly […] Now over the last 2 years the
microbiology department has changed and there’s a
new set of individuals there who are more proactive
and much more amenable to discussing matters with
the clinician so it could well be that my view about
[always doing two-stage] changes. (Duncan)
Costs to the NHS also played a role in treatment deci-
sions. While the cost of performing a two-stage revision
was considerably higher than a one-stage, it was seen to
bring in more resources to the hospital:
Probably, the hospital gets paid more for doing a two-
stage, right, which is always at the back of the
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surgeon’s mind […] the quality of patient care you can
give, depends on your Trust not being in the red. So,
you don’t want to do operations that lose your Trust
money but your first priority is to get the best for the
patient. Plus, when you’re in indecision, the fact that
the two-stage operation doesn’t cost – that doesn’t, you
know, it brings in more resources to the Trust, means
you feel more relaxed about that option. (James)
At one hospital, the surgeons could not be sure that
patients would have timely access to a bed for a second
operation and so patients were kept in the hospital for
the period between the first and second stage, increasing
costs further:
When we start talking to hospital management they’re
not very happy about two-stage procedures because
it’s extra cost, extra time in hospital […] we usually do
the second stage in about 8 to 10 weeks per surgery and
we keep them in hospital for the whole period of time
because we can’t guarantee that they will get readmitted
at the specific time it was required. (Duncan)
Although it did not seem that economic costs influenced
surgeons’ decisions, they nevertheless acknowledged some
pressure to reduce costs. However a lack of access to
adequate microbiology services presented a more direct
concern and a barrier to the possibilities of performing
one-stage operations.
Influence of literature, peers and training
Surgeons reported that they were influenced by pub-
lished results of comparative studies of one- and two-
stage revision surgery. They obtained this information at
conferences and from scientific journals. Professional
colleagues, particularly those more senior, also appeared
to be influential:
[Consultant Q] himself is moving towards more
one-stages and I think that’s sort of leaning more of
us towards thinking about one-stages a, a bit more…
and I think part of that is the results. […] We were all
brought up, you know, 10 years, 15 years ago that
two-stage is the gold standard and so on, but there’s
more and more published results showing that
one-stages are probably equivalent in terms of - in a
lot of the cases in terms of microbiological clearance
and so on, particularly if you’re careful that you pick
the cases as we said, the more difficult ones. (Saul)
Otherwise everyone else has gone - pretty much gone
for two-stage based on, I guess, the most published
literature […] Although I, as you do as a registrar,
I read all the one-stage papers – […] but they’ve
certainly been pushed into the background compared
to the two-stage papers, which have sort of dominated
the literature for the longest period of time. So I end
up doing two for most people. (Harrison)
Managing uncertainty
Of the 12 surgeons interviewed, six surgeons from three
different centres used a custom-made articulating spacer
(CUMARS). This consists of the same implants that
would be used for a definitive reconstruction but that
the surgeon chooses to cement (or fix) in more loosely
than they would normally for a definitive primary or revi-
sion hip replacement [9]. Of the six surgeons who reported
using this technique four suggested they used it almost
exclusively (See Table 1).
Duncan reported that surgeons in the hospital where
he worked had used a version of the CUMARS tech-
nique for around 15 years. However, although he used
this method, most patients stayed in hospital for 8–10
weeks before receiving the second stage:
Yes we’ve been doing [the CUMARS] method for the
last 15 years so it’s nothing new to us.
Right, so basically all your two-stage are loosely
cemented, and would you say if patients are happy
with the first stage you would leave it with them?
Well if they’re very elderly and infirm then yes we
would. But that doesn’t happen often. (Duncan)
Tom explained that the CUMARS approach allowed
him to modify how he fixed the spacer – which is an ar-
ticulating ‘Exeter’ prosthesis – depending on his assess-
ment of likely longer-term outcome; so a one-stage may
remain as a one-stage in an older patient, whereas a
younger patient may need a second revision later on:
So, if you were faced with an elderly patient who was
very frail, you might try and do what is essentially a
one-stage operation, using the spacer device to walk
on and fix it as well as you could, and maybe that
patient will never come to a second stage. A younger
patient […] you might accept that it’s much more
likely that you’re going to go to a second stage […]
and so therefore, you would maybe not fix the hip
quite so well and plan for a two-stage. So, it’s shades
of grey rather than black and white situation and
it’s a slightly odd approach too, the fixation of the
implants. (Tom)
It appears that surgeons may use the CUMARS tech-
nique as it allows more flexibility in the longer term.
This enables surgeons to leave open their options for
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further revisions, in the face of uncertainty about the de-
finitive surgical solution and their uncertainty about certain
patients’ outcomes.
Personal experiences of using CUMARS also prompted
some surgeons to rethink their decisions about using one-
stage or two-stage revision surgery:
It’s one’s personal experience with that, and seeing a
reasonable number of people be happy with those
spacers for a long time that, I guess will give you a bit
of confidence to, just perform single-stage revisions.
You know, if people are doing well after that procedure,
you often wonder, ‘Well, if I had, just done things
slightly differently, then they would have a better
cemented implant, that is now likely to last an awful
long time. And, why don’t I just stick with a single-stage,
or tend to go more towards a second-stage?’And that’s
what I’ve tended to do, is drift in that direction. (Brian)
The surgeons who used CUMARS felt that it benefited
patients, particularly outcomes such as pain and mobility.
They also reported that use of an articulating implant
avoided problems associated with cement spacers such as
erosion of the acetabulum and pain:
The beauty of having a [CUMARS] is that essentially
they’re happy, you know. They walk home. […] I’ve
not had to feel sorry for a patient because they were
struggling with pain because of something that I’ve
put in. (Harrison)
Some of the cement spacers are, that are made, are
designed to go in as articulating spacers up against
the patient’s host acetabulum and those have got a
terrible reputation for erosion on the acetabulum,
pain, failure to allow patients to mobilise. (Tom)
Views about a randomised controlled trial
A lack of evidence for superiority
When asked which technique they used most often, all
surgeons reported that they most frequently performed
two-stage revisions, and they defined CUMARS as a two-
stage method. Surgeons quoted published re-infection
rates for each of the two methods and thought that the
two-stage method provided ‘slightly’ better outcomes,
particularly in terms of eradication of infection. How-
ever, surgeons also questioned this, and reported some
uncertainty in the light of the absence of comparative
evidence:
My bias would be that, if I just intuitively if you said,
‘What are you doing for this patient?’ I’d just go,
‘two-stage’ because that’s what I’ve always done.
That’s what I’ve been taught. That’s what I’ve read
about. And that’s what appears to be slightly better.
But I realise that scientifically there’s no big comparative
trial. (Harrison)
Well, I suppose the truth is, we do not know which
technique, one or two-stage, is better. We know the
two-stage probably has a slightly better chance of
eradication of infection than one-stage by about 10%,
so that is the reason to do it. (Steven)
A shift in practice
While some surgeons felt that two-stage revision pro-
vides a slightly better chance of eradicating infection,
others suggested that over time they had seen increasing
evidence that one-stage revisions were equally effective
and that this would be the ideal way to treat PJI. Reasons
for this included improved surgical techniques, increasing
evidence for the effectiveness of one-stage revision and
the influence of colleagues’ successful results when using
one-stage revision.
I did feel more comfortable with a two-stage revision
generally and always have done, but increasingly over
the last couple of years I have thought more about
doing one stages […] and one colleague in the unit has
done probably more one stages than the rest of us and
seeing that his patients seem to be doing well. (Saul)
Ideally the best way would be to do the operations
as a single stage with a very low recurrence
rate. (Duncan)
I’m getting an impression that there’s increasing
evidence that it’s [one-stage] an equally successful way
of eradicating the infection in an awful lot of people.
That it’s as good. (Brian)
I’m up for change. And this study is quite timely,
because I think there is a general shift, at a lot of the
meetings that we go to, with some people doing more
one-stages, I think, than they used to […] I think we’re
getting better at our surgery. […] I think with OSCAR
[ultrasonic cement removal], you’re more confident
about getting your cement out. (Tim)
Those who talked about their change in attitude most
often referred to increasing published evidence and the
observed success rates of their colleagues as their main
influence. We did not observe that years of experience
or caseload had influenced a shift in willingness to consider
more one-stage revisions amongst surgeons who spoke
about this, compared to those who did not. However, we
did not ask surgeons directly if they felt their years of
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practice or caseload had influenced their decision-making
with regard to one and two-stage revision for infection.
A future trial and equipoise in principle
All surgeons felt that a future randomised controlled trial
comparing one-stage with two-stage revision is needed.
At the moment what we’re doing is not randomising
and unfortunately rationalising to say that ‘this’ is better
than ‘this’, but there are no good studies. So we need
the evidence. (Dave)
To conduct an ethical randomised trial, there must be
clinical equipoise in place [30]. Clinical equipoise is a state
of uncertainty within the clinical community about the
relative therapeutic merits of treatment options. Eligibility
of a patient for a randomised trial depends on the exist-
ence of uncertainty about the best treatment option for
that patient. When asked if they would be able to identify
patients as eligible for randomisation in a trial comparing
one-stage with two-stage revision surgery for infection,
the majority were willing to put patients forward for ran-
domisation when they were not convinced there was a
best clear option, and where clinical equipoise existed.
So you’re quite happy to randomise patients if they’re
suitable?
Yeah, but only obviously where I’m not convinced
that there’s a clear best option. (James)
I’ve got a fairly open mind to that. […] Whilst in the
majority of patients I guess I would be prepared to
randomise them, there are, you know, occasional
cases where you might feel that it’s not the right
thing to do. (Brian)
How would you feel about randomising your patients
into one type of surgery or another?
I’d, I’d be fairly happy about that, I think. I mean, if,
er, unless there’s an obvious, you know, well, as long
as there’s an opt-out in cases that you feel extremely
strongly about, which there normally is [hmm] in
these sorts of studies. (Howard)
I think it’s a good idea, but I think it’s actually very
difficult, because, the patients are all so different
[yeah], you know. It’s not just their, the infection. It’s
the organism type they’ve got. It’s their age. It’s their
comorbidities. It’s their ability to deal with a two-stage
rather than a one-stage procedure. (Alex)
Some surgeons were asked what proportion of patients
with PJI they would be happy to randomise to a trial
comparing one-stage with two-stage revision surgery for
infection. The majority of those asked, stated they would
be happy to randomise most patients:
Right okay, what proportion of patients that you treat
for infection each year would, would you be happy to
randomise do you think?
All of them. (Duncan)
But in general, yes, I think I would be happy to
randomise most of them. But yes, certainly, and the,
the nasty gram-negatives, no, but otherwise most of
them, yes. (Tim)
I think for, for a lot of the infections I would, I would
be fairly happy to put most of them in, you know, a
lot of them into that. Fortunately there aren’t huge
numbers who fall into the really difficult bone or soft
tissue category. (Saul)
Discussion
Our study highlights that surgeons balance multiple factors
when choosing a surgical strategy for treatment of PJI.
Factors included possible outcomes, multiple patient-
related factors, their own knowledge and expertise, available
infrastructure and the infecting organism (see Fig. 1).
Findings also indicate that there is no standard surgical
response to PJI and surgeons try to find the ‘best fit’ for
each individual. The absence of a strong evidence base
makes any well intentioned attempt at developing more
specific guidelines on using one-stage and two-stage revi-
sion surgery for PJI a difficult, if not impossible task.
Surgeons suggest that their willingness to consider a
one-stage revision for patients with PJI has increased
over recent years. With the more widespread adoption
of a CUMARS approach, more efficient microbiology
services, and more publicised research results that show
equally favourable results for one-stage revisions, some
surgeons are re-considering how they choose between
one-stage or two-stage revision. This may relate to the
trend seen in National Joint Registry data, which shows
a modest but consistent year-on-year increase in the
proportion of one-stage procedures conducted for PJI
[31]. We suggest that the use of CUMARS enables sur-
geons to leave their treatment options open, while trying
to reduce the negative impact of treatment on patients’
well-being. It seems possible that the use of CUMARS
has prompted orthopaedic surgeons to rethink the debate
about one-stage versus two-stage revision surgery. The
study suggests that surgeons use CUMARS as a way of
managing uncertainty in the absence of definitive evidence
for the superiority of one surgical technique over the other.
There is a need for a randomised trial to compare
one-stage with two-stage revision techniques to identify
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the most clinically and cost-effective treatment for PJI.
Surgeons in this study were enthusiastic and welcomed
the idea of a randomised trial. All surgeons described
equipoise in principle for a selection of patients. While
this might mean that recruiting enough patients to a trial
of this kind may be challenging, it will be interesting to
see whether the proportion of patients that surgeons con-
sider to be eligible for randomisation changes over the
course of the trial as surgeons become more comfortable
with randomisation. Although one-stage revision was seen
as the ideal way to treat PJI, surgeons thought that an ab-
sence of definitive studies meant that a change in practice
was not yet warranted.
These findings compliment and build on our previous
study of the impact of PJI and treatment on patients [10],
which showed how PJI can adversely affect all aspects of
patients’ lives causing physical and psychological distress.
This echoes the concerns of surgeons’ in this study that
decisions about the potential benefit of revision treatment
– especially two-stage – must be balanced against the im-
pact of that treatment on patients.
Strengths and limitations
In this study, qualitative methods enabled us to charac-
terise complex decision-making processes and the ac-
ceptability of a future randomised controlled trial. The
sample size was small but achieved saturation and was
appropriate to the qualitative study design [26, 28].
Specifically, the sample included surgeons with experi-
ence in one-stage and two-stage revision, from 5 differ-
ent NHS hospitals. Robust thematic analysis ensured
that saturation occurred, so that no new themes were
identified in the later interviews. Although surgeons
were asked to describe their decisions and we did not
directly observe decisions being made in practice, or
compare their decisions with hospital data, our focus
was on how decisions were made and opinions about a
future trial. As such, use of self-report was appropriate
to the research question and approach.
Conclusion
This article addresses an area in need of more research.
Although clinical reviews are of great value [6, 32, 33],
systematic reviews [16, 17] and the challenges faced by
patients with PJI [10] highlight the need for strong evi-
dence about one-stage and two-stage surgery. To design
research that will impact on treatment we first need to
understand reasons for current practice and assess feasi-
bility of a future trial [22, 34]. Our study demonstrates
that surgeons’ decisions are based on a complex com-
bination of their own training and clinical experience,
multiple patient-related factors, hospital infrastructure
and the infecting organism. Our findings also show that
some surgeons’ willingness to consider more one-stage
revisions for infection has increased over recent years,
influenced by better microbiology services, increasing
evidence of equivalent effectiveness of eradication, and
surgeons’ observations of colleagues’ success in using one-
stage revision. We also find that the use of CUMARS has
prompted orthopaedic surgeons to rethink their choice of
revision surgery, and is possibly used as a way of
managing uncertainty in the absence of definitive
evidence for the superiority of one surgical technique
over the other. Surgeons support the need to conduct a
Fig. 1 Factors involved when choosing a surgical strategy for the treatment of prosthetic joint infection
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randomised trial comparing treatments for PJI. The next
step is to conduct a robust, randomised trial to improve
the evidence base for treating patients who develop a PJI
after hip replacement.
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